Return to homepagePandemic Pact

Decision support for prediction and management of Long Covid Syndrome (LCS)

Grant number: 101057553

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2026
  • Known Financial Commitments (USD)

    $7,008,151.18
  • Funder

    European Commission
  • Principal Investigator

    Liira Helena
  • Research Location

    Finland
  • Lead Research Institution

    HUS-YHTYMA
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Physicians

Abstract

We will develop tools and knowledge to support physicians in accurately managing Long COVID syndrome (LCS) which has a significant impact on sufferers as well as their surroundings. Although much is now known regarding appropriate clinical management of acute COVID-19, very little is known about clinical manifestations, risk factors and underlying mechanisms for development of the highly heterogenous LCS. In this project, we aim to understand and mechanisms of LCS by combining front-line expertise from the fields of clinical medicine, virology, metabolism and immunology. We will study the pathogenesis of LCS by conducting geographically diverse cohort and registry studies, by conducting mechanistic studies, by using novel high-throughput methods for biomarker analysis, and by conducting interventional and follow-up studies on LCS patients. We will combine results from clinical and mechanistic studies to identify molecular and physiological parameters and/or pathways to decipher the mechanisms underlying LCS. We will exploit the high-throughput omics technologies to identify the predisposing factors and biomarkers that lead to the development of LCS. We will collect data from the cohort, mechanistic, biomarker and interventional studies and use these to validate the predictive artificial intelligence algorithms and to produce information and gain understanding on the combination of factors that lead to certain clustering of patients into different groups with specific symptoms. A machine learning and AI-informed Long Covid Prediction Support (LCPS) tool will be developed for the use of clinicians to predict the LCS and its possible clinical manifestations in patients. It will also help in the choice of personalized treatments for LCS patients. Additionally, an interactive graphic user interface infographic will also be available to clinicians and patients; this will communicate novel and understandable information about LCS and recommendations for patient management.

17 Publications linked via Europe PMC

Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study.

Single-cell analysis of the human immune system reveals sex-specific dynamics of immunosenescence.

Maternal antibodies shape infant immune response development in an epitope-specific manner.

Characterization of sympathicotonia in post-covid condition (long covid) and healthy controls using long-term electrodermal activity (EDA) follow-up.

Optimized summary-statistic-based single-cell eQTL meta-analysis.

Basel Long COVID Cohort Study (BALCoS): protocol of a prospective cohort study.

DDHD2 provides a flux of saturated fatty acids for neuronal energy and function.

Facilitators and barriers for return to work among patients with post-COVID-19 condition: a qualitative interview study.

The K18-hACE2 mouse model of SARS-CoV-2 infection to illustrate the role and response of the vasculature in neurotropic viral infection